Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 9/20 | 0.48 |
| ▸ | MAOA | P21397 | 7/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.37 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471461 | 1.00 | CYP1A2 (0.50) | CYP1A2CYP2D6TSHRCYP3A4MAOB | |
| SCHEMBL2477319 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP2D6TSHRCYP3A4MAOB | |
| SCHEMBL2474613 | 0.76 | CYP1A2 (0.53) | CYP1A2CYP2D6TSHRCYP3A4MAOB | |
| SCHEMBL2474959 | 0.76 | MAOB (0.52) | TSHRCYP3A4MAOBMAOAKDM1A | |
| SCHEMBL10062065 | 0.73 | CYP1A2 (0.62) | CYP1A2CYP2D6TSHRCYP3A4MAOB | |
| SCHEMBL3469029 | 0.72 | CSNK1E (0.49) | CYP1A2CYP2D6TSHRCYP3A4MAOB | |
| SCHEMBL11098310 | 0.70 | EPHX1 (0.42) | CYP1A2MAOATAAR1SLC18A2SIGMAR1 | |
| SCHEMBL3172135 | 0.70 | GRIN1 (0.52) | CYP1A2CYP2D6TSHRCYP3A4MAOB | |
| N-Benzylpropargylamine SCHEMBL669952 | 0.69 | PYCR1 (0.64) | CYP1A2CYP2D6TSHRCYP3A4MAOB | |
| SCHEMBL21880070 | 0.69 | TAAR1 (0.54) | CYP2D6CYP3A4MAOAKDM4ETAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266506-B2 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | PIRAMAL IMAGING SA (CH) | 2019-04-23 | — | — | US | disclosed |
| US-20180022719-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PIRAMAL IMAGING SA (CH) | 2018-01-25 | — | — | US | disclosed |
| EP-2388245-B1 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | PIRAMAL IMAGING SA (CH) | 2017-07-12 | — | — | EP | disclosed |
| US-9682944-B2 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | PIRAMAL IMAGING SA (CH) | 2017-06-20 | — | — | US | disclosed |
| EP-2217549-B1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PIRAMAL IMAGING SA (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-20150030539-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PIRAMAL IMAGING SA (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8784775-B2 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | PIRAMAL IMAGING SA (CH) | 2014-07-22 | — | — | US | disclosed |
| EP-2388245-A1 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | Bayer Pharma AG (DE) | 2011-11-23 | — | — | EP | disclosed |
| US-20110254522-A1 | STANDBY POWER SUPPLY CIRCUIT | HON HAI PRECISION INDUSTRY CO., LTD. (TW) | 2011-10-20 | — | — | US | disclosed |
| EP-2374779-A1 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | Bayer Pharma Aktiengesellschaft (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-20100233086-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2217549-A2 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090191129-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | Lantheus Biosciences Ltd. (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009052970-A2 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-04-30 | — | — | WO | disclosed |
| EP-2053033-A1 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | Bayer Schering Pharma AG (DE) | 2009-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022719-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | CYP1A2 4196/4885CYP2D6 4401/4885TSHR 3272/4885 |
| US-10266506-B2 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | PMP22, MEN1, VHL | CYP1A2 4196/4885CYP2D6 4401/4885TSHR 3272/4885 |
| US-20150030539-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | CYP1A2 4196/4885CYP2D6 4401/4885TSHR 3272/4885 |
| US-20090191129-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | CYP1A2 4196/4885CYP2D6 4401/4885TSHR 3272/4885 |
| US-20100233086-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | CYP1A2 4196/4885CYP2D6 4401/4885TSHR 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.